Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study)

Conference Correspondent  - AACR & ASCO 2021 - Midyear Review

Capmatinib offers deep and durable responses with a manageable toxicity for patients with MET exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy.

Capmatinib is a highly potent and selective MET inhibitor. Previous data from the GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) and manageable toxicity profile for capmatinib in patients with MET exon 14–mutated non–small-cell lung cancer (NSCLC) who had received 1 to 2 prior lines of treatment (cohort 4) and in treatment-naïve patients (cohort 5b). At the American Society of Clinical Oncology 2021 annual meeting, researchers reported additional efficacy results for capmatinib in MET exon 14–mutated NSCLC, including duration of response (DOR) and progression-free survival (PFS), as well as the updated ORR results.1

GEOMETRY mono-1 was a phase 2, multicohort, multicenter study evaluating capmatinib in patients with MET exon 14–mutated or MET-amplified advanced NSCLC across 6 cohorts. Adult patients with Eastern Cooperative Oncology Group performance status 0 or 1, wild-type ALK and EGFR, and stage IIIB or stage IV NSCLC were eligible. Patients with MET exon 14–mutated NSCLC (centrally confirmed) were assigned (regardless of MET amplification status/gene copy number) to cohorts 4 and 5b. These patients received capmatinib tablets 400 mg twice daily. The primary efficacy end point was ORR by blinded independent review committee (BIRC) per RECIST version 1.1. A key secondary end point was DOR by BIRC.1

As of November 8, 2018, 97 patients with MET exon 14–mutated NSCLC were evaluable for efficacy: 69 patients in cohort 4; 28 patients in cohort 5b.1 In cohort 4, the ORR by BIRC was 40.6% (95% confidence interval [CI], 28.9%-53.1%). In cohort 5b, the ORR by BIRC was 67.9% (95% CI, 47.6%-84.1%).1 While still immature at the time of this analysis, data regarding DOR are promising: median DOR (95% CI) by BIRC was 9.7 months (5.6-13.0) and 8.4 months (12.6-not evaluable) for cohorts 4 and 5b, respectively.1 Median PFS (95% CI) by BIRC was 5.4 months (4.2-7.0) and 12.4 months (8.2-23.4) for cohorts 4 and 5b, respectively.1

Safety profile remains favorable and unchanged. The most common adverse events (≥25% all grades) seen with capmatinib across all cohorts (n = 373) were peripheral edema (54%), nausea (45%), vomiting (28%), and increased blood creatinine (27%).1 The majority of these adverse events were grade 1 or 2.1

Researchers concluded that these data confirm capmatinib’s status as a promising new treatment for patients with MET exon 14–mutated advanced NSCLC regardless of the line of therapy, offering deep and durable responses with a manageable toxicity profile.1

Reference

1. Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study. Presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021. Abstract 9020.

Related Items
2021 Midyear Review: Non–Small-Cell Lung Cancer
Conference Correspondent  published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Clinical Outcomes for Plasma-Based Genomic Profiling versus Tissue Testing in Advanced NSCLC (NILE)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Pooled Analyses of Immune-Related Adverse Events and Efficacy from IMpower130, IMpower132, and IMpower150
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Anti–PD-L1 Therapy in Combination with Chemotherapy versus Immunotherapy Alone in First-Line NSCLC with PD-L1 Score 1% to 49%
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Racial Disparities in Biomarker Testing and Clinical Trial Enrollment in NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Rucaparib in High Genomic Loss of Heterozygosity and/or BRCA1/2-Mutated NSCLC (Lung-MAP Sub-Study, S1900A)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.